hydroxychloroquine and Chronic Hepatitis C
hydroxychloroquine has been researched along with Chronic Hepatitis C in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The therapeutic effect of pegylated interferon (peg-IFN) alfa-2a combined with ribavirin (RBV) on chronic hepatitis C Egyptian patients is low and further efforts are required to optimize this therapy for achievement of higher rates of virological response." | 7.83 | Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. ( Abd-Ellah, MF; Eid, MS; Gad, MA; Helal, GK, 2016) |
"The therapeutic effect of pegylated interferon (peg-IFN) alfa-2a combined with ribavirin (RBV) on chronic hepatitis C Egyptian patients is low and further efforts are required to optimize this therapy for achievement of higher rates of virological response." | 3.83 | Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. ( Abd-Ellah, MF; Eid, MS; Gad, MA; Helal, GK, 2016) |
Research
Studies (6)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
Authors
Authors | Studies |
---|---|
Molina-Iturritza, E | 1 |
San-José-Muñiz, I | 1 |
Ganchegui-Aguirre, M | 1 |
Balerdi-Sarasola, L | 1 |
Ortiz-de-Zárate-Ibarra, Z | 1 |
Gainzarain-Arana, JC | 1 |
Portu-Zapirain, J | 1 |
Cui, X | 1 |
Sun, J | 1 |
Minkove, SJ | 1 |
Li, Y | 1 |
Cooper, D | 1 |
Couse, Z | 1 |
Eichacker, PQ | 1 |
Torabi-Parizi, P | 1 |
Lin, KM | 1 |
Cheng, TT | 1 |
Lin, JC | 1 |
Chen, CJ | 1 |
Helal, GK | 1 |
Gad, MA | 1 |
Abd-Ellah, MF | 1 |
Eid, MS | 1 |
Yang, D | 1 |
Arkfeld, D | 1 |
Fong, TL | 1 |
Rizvi, R | 1 |
Hojjati, M | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
1 review available for hydroxychloroquine and Chronic Hepatitis C
Article | Year |
---|---|
Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
Topics: Alphapapillomavirus; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; COVID-19; | 2021 |
Other Studies
5 other studies available for hydroxychloroquine and Chronic Hepatitis C
Article | Year |
---|---|
Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coinfe | 2020 |
Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Topics: Adalimumab; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumato | 2015 |
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Genotype; | 2016 |
Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-α2a treatment for chronic hepatitis C infection.
Topics: Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Autoantibodies; Drug Carriers; Hepati | 2010 |
Interferon-α induced lupus in a patient with chronic hepatitis C virus.
Topics: Antirheumatic Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyd | 2011 |